Cacipliq 20® belongs to the family of ReGeneraTing Agents (RGTA®), which are engineered biodegradable sugar based polymers.

Cacipliq 20® protects extracellular matrix proteins from the inside, hence restoring the matrix architecture. It preserves the natural cellular micro-environment of the wound and the endogenous factors needed for tissue regeneration.

Cacipliq 20® is a sterile wound healing solution.

Cacipliq 20® is a class III CE marked Medical Device.

Applied twice a week (every 3 to 4 days), Cacipliq 20® is a unique product which provides an easy-to-use, effective tissue regenerating solution for rapid wound healing.

Warnings and contraindications exist, please read the instructions. 

Chronic ulcers showing no tendency to heal after 6 months of standard care, or still unhealed after 12 months:

• Pressure ulcers.
• Peripheral arterial disease (such as – Stage IV Leriche & Fontaine) ulcers.
• Diabetic ulcers (including amputation).

• Reducing lesion induced pain
• Reducing care time
• Excellent safety record
• Easy to use

The efficacy of Cacipliq 20® has been highlighted by three clinical trials, and various case studies.

Please find below a selection of clinical publications of Cacipliq 20®.